Showing 101 - 120 results of 33,120 for search '(( significant challenges decrease ) OR ( significant causes increased ))', query time: 0.77s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107
  8. 108

    A possible cause of epistaxis: increased masked hypertension prevalence in patients with epistaxis by Baran Acar (10419356)

    Published 2022
    “…Conclusion This study demonstrates increased masked hypertension prevalence in patients with epistaxis. …”
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114

    Mast cell density and tactile sensitivity decreased after 10 preventative imatinib treatments followed by repeated MI challenges. by Jaclyn M. Kline (9565161)

    Published 2020
    “…(B) Tactile sensitivity in sensitized mice preventatively treated with imatinib or NT and then 10 daily MI challenges. Results reported as mean ± SEM of the percent decrease from baseline in the withdrawal threshold for each treatment group, n = 18/treatment group. …”
  15. 115
  16. 116
  17. 117

    Table1_One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes.docx by Alice Castaldo (9956004)

    Published 2024
    “…</p><p>Results: Beyond the improvement of BMI and lung function with LI treatment and even more with ETI, we found that the 3 years of LI treatment significantly improved liver function parameters (total and conjugated bilirubin, ALT, AP, and GGT), while the subsequent ETI treatment caused a significant increase of such parameters.…”
  18. 118

    Table2_One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes.docx by Alice Castaldo (9956004)

    Published 2024
    “…</p><p>Results: Beyond the improvement of BMI and lung function with LI treatment and even more with ETI, we found that the 3 years of LI treatment significantly improved liver function parameters (total and conjugated bilirubin, ALT, AP, and GGT), while the subsequent ETI treatment caused a significant increase of such parameters.…”
  19. 119
  20. 120